Pharmaceutical Preparations · SAN FRANCISCO, CA, United States
$27.53
-10.56% (-$3.25)2026-08-10
Smart-Money SignalNeutral · 50/100— Insider open-market flow is flat over 90 days
Price Performance
Historical data including institutional events
Company Profile
T
Travis Murdoch
CEO & Executive Director
Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases.
It develops and offers BHB-1893 and HRS-1893, an oral small-molecule cardiac myosin inhibitor (CMI) for the treatment of obstructive HCM and non-obstructive HCM.
The company was incorporated in 2024 and is headquartered in San Francisco, California.
